Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)
China · Delayed Price · Currency is CNY 10.88
-0.33 (-2.94%)
Nov 13, 2026, 3:00 PM CST
Jiangsu Yahong Meditech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 315.29 | 272.74 | 189.46 | 11.52 | 0.03 | 0 |
Other Revenue | 4.38 | 4.38 | 12.1 | 2.23 | - | - |
| 319.67 | 277.12 | 201.56 | 13.75 | 0.03 | 0 | |
Revenue Growth | 14.57% | 37.49% | 1365.55% | 52604.89% | 470.51% | - |
Cost of Revenue | 79.95 | 71.97 | 50.32 | 2.93 | 1.83 | 1.19 |
Gross Profit | 239.72 | 205.15 | 151.25 | 10.83 | -1.81 | -1.19 |
Selling, General & Admin | 453.69 | 365.32 | 262.75 | 117.55 | 88.29 | 63.86 |
Research & Development | 333.95 | 282.63 | 311.92 | 364.59 | 243.89 | 190.74 |
Other Operating Expenses | 1.85 | 0.83 | 0.26 | -0.31 | 0.27 | 0.03 |
Operating Expenses | 786.54 | 650.82 | 577.62 | 482.29 | 332.46 | 254.64 |
Operating Income | -546.82 | -445.66 | -426.38 | -471.47 | -334.27 | -255.82 |
Interest Expense | - | -8.27 | -6.75 | -2.97 | -0.77 | -0.48 |
Interest & Investment Income | 13.9 | 22.71 | 38.65 | 48.02 | 26.64 | 14.44 |
Currency Exchange Gain (Loss) | -3.45 | -3.45 | -0.64 | -0.79 | 9.84 | -2.03 |
Other Non Operating Income (Expenses) | -11.56 | -2.46 | -2.09 | -0.76 | -0.16 | -0.36 |
EBT Excluding Unusual Items | -547.92 | -437.14 | -397.21 | -427.96 | -298.71 | -244.25 |
Gain (Loss) on Sale of Investments | 6.58 | 6.82 | 9.72 | 19.58 | 47.53 | 4.1 |
Gain (Loss) on Sale of Assets | -0.6 | -0 | 0.05 | - | - | -0.02 |
Asset Writedown | -0.27 | -0 | - | -0.03 | -0.01 | - |
Legal Settlements | - | - | -1.99 | - | - | - |
Other Unusual Items | -1.45 | -3.09 | 2.63 | 6.9 | 5.93 | 5.42 |
Pretax Income | -543.66 | -433.41 | -386.8 | -401.5 | -245.27 | -234.75 |
Income Tax Expense | -0.31 | -0.66 | -0.8 | -0.67 | 1.28 | 0.19 |
Earnings From Continuing Operations | -543.35 | -432.75 | -386 | -400.83 | -246.55 | -234.95 |
Minority Interest in Earnings | 14.18 | 16.36 | 1.94 | 0.4 | - | - |
Net Income | -529.18 | -416.38 | -384.06 | -400.43 | -246.55 | -234.95 |
Net Income to Common | -529.18 | -416.38 | -384.06 | -400.43 | -246.55 | -234.95 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 562 | 563 | 565 | 572 | 573 | 461 |
Shares Outstanding (Diluted) | 562 | 563 | 565 | 598 | 573 | 461 |
Shares Change | -0.65% | -0.38% | -5.50% | 4.24% | 24.46% | 0.61% |
EPS (Basic) | -0.94 | -0.74 | -0.68 | -0.70 | -0.43 | -0.51 |
EPS (Diluted) | -0.94 | -0.74 | -0.68 | -0.70 | -0.43 | -0.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -555.56 | -430.92 | -430.74 | -499.82 | -268.57 | -213.92 |
Free Cash Flow Per Share | -0.99 | -0.77 | -0.76 | -0.84 | -0.47 | -0.46 |
Gross Margin | 74.99% | 74.03% | 75.04% | 78.72% | - | - |
Operating Margin | -171.06% | -160.82% | -211.54% | -3428.02% | -1280959.60% | -5592976.39% |
Profit Margin | -165.54% | -150.25% | -190.54% | -2911.54% | -944816.18% | -5136625.82% |
Free Cash Flow Margin | -173.79% | -155.50% | -213.70% | -3634.18% | -1029206.22% | -4676788.98% |
EBITDA | -524.67 | -426.41 | -410.97 | -463.44 | -330.15 | -253.25 |
EBITDA Margin | -164.13% | -153.87% | -203.89% | - | - | - |
D&A For EBITDA | 22.15 | 19.26 | 15.4 | 8.03 | 4.11 | 2.57 |
EBIT | -546.82 | -445.66 | -426.38 | -471.47 | -334.27 | -255.82 |
EBIT Margin | -171.06% | -160.82% | -211.53% | - | - | - |
Revenue as Reported | 60.71 | 277.12 | 201.56 | 13.75 | 0.03 | 0 |
Advertising Expenses | - | 125.67 | 72.22 | 3.95 | 2.71 | - |